Benoit You

Employment

• Hospices Civils de Lyon

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (92)

• Response to Correspondence on “Differences in first-line chemosensitivity assessed by KELIM in advanced serous ovarian cancer: evidence from Western and Japanese trials in a Gynecologic Cancer InterGroup (GCIG) Meta-analysis”
  International Journal of Gynecological Cancer 2026 DOI: 10.1016/j.ijgc.2026.104866
  +Save
• Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis
  International Journal of Gynecological Cancer 2026 DOI: 10.1016/j.ijgc.2026.104805
  +Save
• Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis
  International Journal of Gynecological Cancer 2026 DOI: 10.1016/j.ijgc.2025.102719
  +Save
• Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial
  JCO Precision Oncology 2026 DOI: 10.1200/PO-25-00414
  +Save
• ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
  Clinical Cancer Research 2026 DOI: 10.1158/1078-0432.CCR-25-2959
  +Save
• Supplementary Table S1 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
  2026 DOI: 10.1158/1078-0432.31910977
  +Save
• Supplementary Figure S9 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
  2026 DOI: 10.1158/1078-0432.31910980
  +Save
• Supplementary Figure S8 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
  2026 DOI: 10.1158/1078-0432.31910983
  +Save
• Supplementary Figure S7 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
  2026 DOI: 10.1158/1078-0432.31910986
  +Save
• Supplementary Figure S5 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
  2026 DOI: 10.1158/1078-0432.31910992
  +Save